Literature DB >> 9698765

Cytokines produced by susceptible and resistant mice in the course of Paracoccidioides brasiliensis infection.

V L Calich1, S S Kashino.   

Abstract

Paracoccidioidomycosis (PCM) is the most prevalent deep mycosis in Latin America and presents a wide spectrum of clinical manifestations. We established a genetically controlled murine model of PCM, where A/Sn mice develop an infection which mimics the benign disease (immune responses which favor cellular immunity) and B10.A animals present the progressive disseminated form of PCM (preferential activation of B cells and impairment of cellular immune responses). To understand the immunoregulatory phenomena associated with resistance and susceptibility in experimental PCM, A/Sn and B10.A mice were studied regarding antigen-elicited secretion of monokines (TNF-alpha and TGF-beta) and type-1 (IL-2 and IFN-gamma) and type-2 (IL-4,5,10) cytokines. Total lymph node cells from resistant mice infected i.p. with P. brasiliensis produced early and sustained levels of IFN-gamma and IL-2; type-2 cytokines (IL-4 and IL-5) started to appear 8 weeks after infection. In contrast, susceptible mice produced low levels of IFN-gamma concomitant with significant levels of IL-5 and IL-10 early in the infection. In the chronic phase of the disease, susceptible animals presented a transitory secretion of IL-2, and IL-4. In the pulmonary infection IL-4, IL-5 and IL-10 were preferentially detected in the lung cells washings of susceptible animals. After in vitro challenge with fungal antigens, normal peritoneal macrophages from B10.A mice secreted high levels of TGF-beta and low levels of TNF-alpha. In contrast, macrophages from A/Sn animals released high levels of TNF-alpha associated with a small production of TGF-beta. The in vivo depletion of IFN-gamma not only abrogated the resistance of A/Sn mice but also diminished the relative resistance of B10.A animals. The in vivo depletion of IL-4 did not alter the disease outcome, whereas administration of rIL-12 significantly enhanced resistance in susceptible animals. Taken together, these results suggest that an early secretion of high levels of TNF-alpha and IFN-gamma followed by a sustained secretion of IL-2 and IFN-gamma plays a dominant role in the resistance mechanisms to P. brasiliensis infection. In contrast, an early and ephemeral secretion of low levels of TNF-alpha and IFN-gamma associated with production of IL-5, IL-10 and TGF-beta characterizes the progressive disease of susceptible animals.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9698765     DOI: 10.1590/s0100-879x1998000500003

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  39 in total

1.  Anti-idiotypic antibodies in patients with different clinical forms of paracoccidioidomycosis.

Authors:  A R Souza; J L Gesztesi; G M del Negro; G Benard; J Sato; M V Santos; T B Abrahão; J D Lopes
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

2.  Cytokine quantification in the supernatant of mononuclear cell cultures and in blood serum from patients with Jorge Lobo's disease.

Authors:  Fátima Regina Vilani-Moreno; José Roberto Pereira Lauris; Diltor Vladimir Araújo Opromolla
Journal:  Mycopathologia       Date:  2004-07       Impact factor: 2.574

3.  High serum interleukin-10 and tumor necrosis factor alpha levels in chronic paracoccidioidomycosis.

Authors:  M C Fornari; A J Bava; M T Guereño; V E Berardi; M R Silaf; R Negroni; R A Diez
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

4.  Cyclosporin A treatment and decreased fungal load/antigenemia in experimental murine paracoccidioidomycosis.

Authors:  T Y C Massuda; L A Nagashima; P C Leonello; M S Kaminami; M S Mantovani; A Sano; J Uno; E J Venancio; Z P Camargo; E N Itano
Journal:  Mycopathologia       Date:  2010-09-11       Impact factor: 2.574

5.  Targeting the Homoserine Dehydrogenase of Paracoccidioides Species for Treatment of Systemic Fungal Infections.

Authors:  Mariane C Bagatin; Arethusa L Pimentel; Débora C Biavatti; Ernani A Basso; Erika S Kioshima; Flavio A V Seixas; Gisele de F Gauze
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

6.  Immunological basis for the gender differences in murine Paracoccidioides brasiliensis infection.

Authors:  Camila Figueiredo Pinzan; Luciana Pereira Ruas; Anália Sulamita Casabona-Fortunato; Fernanda Caroline Carvalho; Maria-Cristina Roque-Barreira
Journal:  PLoS One       Date:  2010-05-21       Impact factor: 3.240

7.  Traffic of leukocytes and cytokine up-regulation in the central nervous system in a murine model of neuroparacoccidioidomycosis.

Authors:  Vinicius Sousa Pietra Pedroso; Márcia Carvalho Vilela; Patrícia Campi Santos; Patrícia Silva Cisalpino; Milene Alvarenga Rachid; Antônio Lúcio Teixeira
Journal:  Mycopathologia       Date:  2013-07-23       Impact factor: 2.574

8.  Therapeutic administration of KM+ lectin protects mice against Paracoccidioides brasiliensis infection via interleukin-12 production in a toll-like receptor 2-dependent mechanism.

Authors:  Kely C Coltri; Leandro L Oliveira; Camila F Pinzan; Patrícia E Vendruscolo; Roberto Martinez; Maria Helena Goldman; Ademilson Panunto-Castelo; Maria-Cristina Roque-Barreira
Journal:  Am J Pathol       Date:  2008-07-03       Impact factor: 4.307

9.  Killing of Paracoccidioides brasiliensis yeast cells by IFN-gamma and TNF-alpha activated murine peritoneal macrophages: evidence of H(2)O (2) and NO effector mechanisms.

Authors:  Ana Paula Moreira; Luciane Alarcão Dias-Melicio; Maria Terezinha S Peraçoli; Sueli A Calvi; Angela Maria Victoriano de Campos Soares
Journal:  Mycopathologia       Date:  2008-05-22       Impact factor: 2.574

10.  Lack of galectin-3 drives response to Paracoccidioides brasiliensis toward a Th2-biased immunity.

Authors:  Luciana Pereira Ruas; Emerson Soares Bernardes; Marise Lopes Fermino; Leandro Licursi de Oliveira; Daniel K Hsu; Fu-Tong Liu; Roger Chammas; Maria-Cristina Roque-Barreira
Journal:  PLoS One       Date:  2009-02-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.